News
October, 2011
Harmony's visit to the Mayo clinic the first week of October had mixed results. First, there was some great news. Imaging showed that there were no remaining visible tumors. There is, however, a cancer indicator that suggests there is/are small amount(s) of medullary cancer cells somewhere. The doctors believe that more imaging should be done in three months to see if anything becomes visible. If something is found, surgery will immediately be scheduled. There is a small chance that the cancer indicator is just residual from the previously removed tumors. The tumors were removed 3 months prior. The cancer indicator is processed in most known patients in a few weeks time. But perhaps Harmony's body has a few non-standard processes going on. Life goes on expecting the best will happen.


November 03, 2011
The Fundraiser raffel Drawing is complete. A HUGE Thank You to all of our sponsors, donors, and participants!

Links

Medullary Thyroid Cancer
info about MTC

Medullary cancer is a rare form of thyroid cancer, accounting for <10% of all thyroid cancers. Unlike the more common papillary and follicular thyroid cancer, medullary thyroid cancer does not respond to radioactive iodine, so the main treatment option is surgery. When medullary thyroid cancer has spread throughout the body (becomes metastatic), there has been little to offer these unfortunate patients as there has been no effective chemotherapy drugs. Recent studies have identified vascular endothelial growth factor receptor (VEGFR) as a target for cancer therapy. VEGFRs are a family of proteins (called tyrosine kinase) that sit on the surface of cells and trigger chemical signals to grow new blood vessels and make existing blood vessels bigger. Drugs that block VEGFRs cause blood vessels to shrink and kills off cancer cells that are supplied by these blood vessels. Motesanib blocks VEGFRs and preliminary reports have shown this drug to be effective in patients with metastatic medullary thyroid cancer. This study reports the results of a Phase II clinical trial of Motesanib in patients with metastatic medullary thyroid cancer.